Recent antiviral strategies against human coronavirus-related respiratory illnesses

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 3, 2008, Pages 248-253

  Golda, Anna ^a   Pyrc, Krzysztof ^a  

^a JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Antiviral drugs; Antiviral strategies; Coronaviruses

Indexed keywords

AGGLUTININ; ANTIVIRUS AGENT; CYANOVIRIN N; ENZYME INHIBITOR; HELICASE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PRADIMICIN A; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; CLINICAL RESEARCH; CORONAVIRUS; DRUG RESEARCH; EPIDEMIC; GENE SILENCING; INFECTION CONTROL; MOLECULAR DOCKING; NONHUMAN; PREVENTIVE HEALTH SERVICE; RESPIRATORY TRACT INFECTION; REVIEW; RNA INTERFERENCE; SEQUENCE HOMOLOGY; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS ENVELOPE; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; CORONAVIRUS INFECTIONS; HUMANS; RESPIRATORY TRACT INFECTIONS;

EID: 42449158129     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3282f7646f     Document Type: Review

References (77)

1. van der Hoek L, Pyrc K, Jebbink MF, et al. Identification of a new human coronavirus. Nat Med 2004; 10:368-373.
2. Woo PC, Lau SK, Chu CM, et al. Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J Virol 2005; 79:884-895.
3. Peiris JS, Lai ST, Poon LL, et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361:1319-1325.
4. Drosten C, Gunther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 2003; 348:1967-1976.
5. Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348:1953-1966.
6. Hamre D, Procknow JJ. A new virus isolated from the human respiratory tract. Proc Soc Exp Biol Med 1966; 121:190-193.
7. McIntosh K, Dees JH, Becker WB, et al. Recovery in tracheal organ cultures of novel viruses from patients with respiratory disease. Proc Natl Acad Sci U S A 1967; 57:933-940.
8. Tyrrell DA, Bynoe ML. Cultivation of a novel type of common-cold virus in organ cultures. BMJ 1965; 5448:1467-1470.
9. Weiss SR, Navas-Martin S. Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev 2005; 69:635-664.
10. Vabret A, Dina J, Gouarin S, et al. Detection of the new human coronavirus HKU1: a report of 6 cases. Clin Infect Dis 2006; 42:634-639.
11. Falsey AR, McCann RM, Hall WJ, et al. The "common cold" in frail older persons: impact of rhinovirus and coronavirus in a senior daycare center. J Am Geriatr Soc 1997; 45:706-711.
12. van der Hoek L, Sure K, Ihorst G, et al. Croup is associated with the novel coronavirus NL63. PLoS Med 2005; 2:e240.
13. Pyrc K, Berkhout B, van der Hoek L. The novel human coronaviruses NL63 and HKU1. J Virol 2007; 81:3051-3057.
14. Woo PC, Lau SK, Tsoi HW, et al. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J Infect Dis 2005; 192:1898-1907.
15. Pyrc K, Jebbink MF, Berkhout B, van der Hoek L. Genome structure and transcriptional regulation of human coronavirus NL63. Virol J 2004; 1:7.
16. Holmes KV, Lai MMC. Coronaviridae: the viruses and their replication. In: Fields BN, Knipe DM, Howley PM, et al., editors. Fields virology, 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996. pp. 1075-1093.
17. Leonard JN, Schaffer DV. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther 2006; 13:532-540.
18. Dykxhoorn DM, Lieberman J. Silencing viral infection. PLoS Med 2006; 3:e242.
19. Chang Z, Hu Z. RNAi therapeutics: can siRNAs conquer SARS? Gene Ther 2006; 13:871-872.
20. Marx J. Interfering with gene expression. Science 2000; 288:1370-1372.
21. Fire A. RNA-triggered gene silencing. Trends Genet 1999; 15:358-363.
22. Naito Y, Ui-Tei K, Nishikawa T, et al. siVirus: web-based antiviral siRNA design software for highly divergent viral sequences. Nucleic Acids Res 2006; 34:W448-W450. Authors designed a web-based antiviral siRNA design engine for highly divergent viral sequences.
23. He ML, Zheng BJ, Chen Y, et al. Kinetics and synergistic effects of siRNAs targeting structural and replicase genes of SARS-associated coronavirus. FEBS Lett 2006; 580:2414-2420. Synergistic effect of multiple siRNAs directed to various genes of SARS-CoV.
24. Pyrc K, Bosch BJ, Berkhout B, et al. Inhibition of human coronavirus NL63 infection at early stages of the replication cycle. Antimicrob Agents Chemother 2006; 50:2000-2008. Identification of several potent inhibitiors of HCoV-NL63 replication.
25. Zhang X, Wu K, Yue X, et al. Inhibition of SARS-CoV gene expression by adenovirus-delivered small hairpin RNA. Intervirology 2007; 50:63-70. Adenoviral vectors as carriers of several short hairpin RNAs targeting SARS-CoV.
26. Cavanagh D. Coronavirus IBV: structural characterization of the spike protein. J Gen Virol 1983; 64 (Pt 12):2577-2583.
27. Vlasak R, Luytjes W, Spaan W, Palese P. Human and bovine coronaviruses recognize sialic acid-containing receptors similar to those of influenza C viruses. Proc Natl Acad Sci U S A 1988; 85:4526-4529.
28. Yeager CL, Ashmun RA, Williams RK, et al. Human aminopeptidase N is a receptor for human coronavirus 229E. Nature 1992; 357:420-422.
29. Hofmann H, Pyrc K, van der Hoek L, et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A 2005; 102:7988-7993.
30. Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426:450-454.
31. Balzarini J. Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol 2007; 5:583-597.
32. van der Meer FJ, de Haan CA, Schuurman NM, et al. Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res 2007; 76:21-29. Several novel carbohydrate-binding agents as potential antiviral agents active against multiple viruses that belong to the order of Nidovirales.
33. van der Meer FJ, de Haan CA, Schuurman NM, et al. The carbohydrate-binding plant lectins and the nonpeptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J Antimicrob Chemother 2007; 60:741-749. Plant lectins and pradimicin A interact with coronaviral envelope proteins and inhibit viral replication during cell entry and egress process.
34. Hwang WC, Lin Y, Santelli E, et al. Structural basis of neutralization by a human antisevere acute respiratory syndrome spike protein antibody, 80R. J Biol Chem 2006; 281:34610-34616.
35. He Y, Li J, Du L, et al. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine 2006; 24:5498-5508.
36. He Y, Li J, Li W, et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol 2006; 176:6085-6092.
37. Zhou L, Ni B, Luo D, et al. Inhibition of infection caused by severe acute respiratory syndrome-associated coronavirus by equine neutralizing antibody in aged mice. Int Immunopharmacol 2007; 7:392-400.
38. Xu Y, Jia Z, Zhou L, et al. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque. Int Immunopharmacol 2007; 7:1834-1840. Equine antibodies inhibit SARS-CoV and protect infected animals from infection.
39. Luo D, Ni B, Zhao G, et al. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2. Viral Immunol 2007; 20:495-502.
40. Zhao G, Ni B, Jiang H, et al. Inhibition of severe acute respiratory syndrome-associated coronavirus infection by equine neutralizing antibody in golden Syrian hamsters. Viral Immunol 2007; 20:197-205.
41. Lin YS, Lin CF, Fang YT, et al. Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity. Clin Exp Immunol 2005; 141:500-508.
42. Kang X, Yang BA, Hu Y, et al. Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display. Clin Vaccine Immunol 2006; 13:953-957. Human monoclonal antibodies generated with the phage display technique inhibit SARS-CoV replication.
43. Coughlin M, Lou G, Martinez O, et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 2007; 361:93-102. Production of several fully human SARS-CoV-S-protein specific antibodies in XenoMouse with a high neutralizing potential.
44. ter Meulen J, van den Brink EN, Poon LL, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med 2006; 3:e237.
45. Doms RW, Moore JP. HIV-1 membrane fusion: targets of opportunity. J Cell Biol 2000; 151:F9-F14.
46. Inoue Y, Tanaka N, Tanaka Y, et al. Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted. J Virol 2007; 81:8722-8729.
47. Eckert DM, Kim PS. Mechanisms of viral membrane fusion and its inhibition. Annu Rev Biochem 2001; 70:777-810.
48. Bosch BJ, Martina BE, Van Der Zee R, et al. Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides. Proc Natl Acad Sci U S A 2004; 101:8455-8460.
49. Tripet B, Kao DJ, Jeffers SA, et al. Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus. J Struct Biol 2006; 155:176-194.
50. Sainz B Jr, Mossel EC, Gallaher WR, et al. Inhibition of severe acute respiratory syndrome-associated coronavirus (SARS-CoV) infectivity by peptides analogous to the viral spike protein. Virus Res 2006; 120:146-155.
51. Yang H, Bartlam M, Rao Z. Drug design targeting the main protease, the Achilles' heel of coronaviruses. Curr Pharm Des 2006; 12:4573-4590.
52. Anand K, Ziebuhr J, Wadhwani P, et al. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003; 300:1763-1767.
53. Wu CY, King KY, Kuo CJ, et al. Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease. Chem Biol 2006; 13:261-268. Stable benzotriazole esters as inhibitors of the main protease.
54. Zhang J, Pettersson HI, Huitema C, et al. Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters. J Med Chem 2007; 50:1850-1864. Tetrapeptide phthalhydrazide ketones, pyridinyl esters and their analogues as inhibitors of the main protease.
55. Ghosh AK, Xi K, Grum-Tokars V, et al. Structure-based design, synthesis, and biological evaluation of peptidomimetic SARS-CoV 3CLpro inhibitors. Bioorg Med Chem Lett 2007; 17:5876-5880. Development of a series of peptidomimetic SARS-CoV main protease inhibitors.
56. Yang S, Chen SJ, Hsu MF, et al. Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor. J Med Chem 2006; 49:4971-4980. Identification of TG-0205221 as a potent inhibitor of SARS-CoV main protease.
57. Hamill P, Hudson D, Kao RY, et al. Development of a red-shifted fluorescence-based assay for SARS-coronavirus 3CL protease: identification of a novel class of anti-SARS agents from the tropical marine sponge Axinella corrugata. Biol Chem 2006; 387:1063-1074. Coumarin derivative esculetin-4-carboxylic acid ethyl ester, from the tropical marine sponge Axinella corrugata, as inhibitor of the main protease.
58. Zhou L, Liu Y, Zhang W, et al. Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors. J Med Chem 2006; 49:3440-3443. Series of isatin derivatives as inhibitors of the main protease.
59. Al Gharabli SI, Shah ST, Weik S, et al. An efficient method for the synthesis of peptide aldehyde libraries employed in the discovery of reversible SARS coronavirus main protease (SARS-CoV Mpro) inhibitors. Chembiochem 2006; 7:1048-1055. Peptide aldehydes as inhibitors of the main protease.
60. Chen L, Li J, Luo C, et al. Binding interaction of quercetin-3-beta-galactoside and its synthetic derivatives with SARS-CoV 3CL(pro): structure-activity relationship studies reveal salient pharmacophore features. Bioorg Med Chem 2006; 14:8295-8306. Quercetin-3-b-galactoside as inhibitors of the main protease.
61. Tsai KC, Chen SY, Liang PH, et al. Discovery of a novel family of SARS-CoV protease inhibitors by virtual screening and 3D-QSAR studies. J Med Chem 2006; 49:3485-3495.
62. Lu IL, Mahindroo N, Liang PH, et al. Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease. J Med Chem 2006; 49:5154-5161.
63. Wei P, Fan K, Chen H, et al. The N-terminal octapeptide acts as a dimerization inhibitor of SARS coronavirus 3C-like proteinase. Biochem Biophys Res Commun 2006; 339:865-872. Identification of the main protease inhibitor, interfering with the main protease dimerisation.
64. Frick DN, Lam AM. Understanding helicases as a means of virus control. Curr Pharm Des 2006; 12:1315-1338.
65. Tanner JA, Zheng BJ, Zhou J, et al. The adamantane-derived bananins are potent inhibitors of the helicase activities and replication of SARS coronavirus. Chem Biol 2005; 12:303-311.
66. Hoffmann M, Eitner K, von Grotthuss M, et al. Three dimensional model of severe acute respiratory syndrome coronavirus helicase ATPase catalytic domain and molecular design of severe acute respiratory syndrome coronavirus helicase inhibitors. J Comput Aided Mol Des 2006; 20:305-319.
67. Wilson L, McKinlay C, Gage P, Ewart G. SARS coronavirus E protein forms cation-selective ion channels. Virology 2004; 330:322-331.
68. Wilson L, Gage P, Ewart G. Hexamethylene amiloride blocks E protein ion channels and inhibits coronavirus replication. Virology 2006; 353:294-306. Identification of hexamethylene amiloride as a potent inhibitor of several coronaviruses.
69. Fleming DM. Managing influenza: amantadine, rimantadine and beyond. Int J Clin Pract 2001; 55:189-195.
70. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69:517-528.
71. de Lang A, Osterhaus AD, Haagmans BL. Interferon-gamma and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells. Virology 2006; 353:474-481. Decreased levels of SARS-CoV cellular receptor after treatment with IL-4 and IFN-γ.
72. Raaben M, Einerhand AW, Taminiau LJ, et al. Cyclooxygenase activity is important for efficient replication of mouse hepatitis virus at an early stage of infection. Virol J 2007; 4:55. Inhibition of murine hepatitis virus with cyclooxygenase inhibitors.
73. Dahl H, Linde A, Strannegard O. In vitro inhibition of SARS virus replication by human interferons. Scand J Infect Dis 2004; 36:829-831.
74. Wong S, Lau S, Woo P, Yuen KY. Bats as a continuing source of emerging infections in humans. Rev Med Virol 2007; 17:67-91.
75. Perlman S. Pathogenesis of coronavirus-induced infections. Review of pathological and immunological aspects. Adv Exp Med Biol 1998; 440:503-513.
76. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. Nat Med 2005; 11:944-951.
77. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat Med 2005; 11:50-55.